The United States has confirmed that tariffs on generic drug imports from India were not raised during recent trade discussions, distinguishing New Delhi from other nations facing potential penalties.
US Secretary of State Marco Rubio stated that the issue was not elevated during talks with Indian External Affairs Minister S.
Jaishankar, though he noted that tariffs might be increased with other countries.
Jaishankar, though he noted that tariffs might be increased with other countries.
The policy shift is part of a broader US strategy aimed at reshoring generic pharmaceutical manufacturing.
President Donald Trump emphasized that the administration intends to bring production back to the United States, with penalties imposed on companies that choose not to establish domestic manufacturing plants.
This approach signals a targeted use of trade leverage to influence corporate supply chain decisions.